molecules of the month


oral, once-daily, allosteric TYK2 inhibitor

Ph. IIb for moderate-to-severe plaque psoriasis

FEP+ supported VLS + core hopping w/ TYK2-JH2 Xtal structure

Press release, March 18, 2023

Nimbus Therapeutics, MA / Takeda, JP

TAK-279, oral, once-daily, allosteric TYK2 inhibitor, Ph. IIb for moderate-to-severe plaque psoriasis, FEP+-supported core hopping + VLS w/ TYK2-JH2 Xtal structure, Press release, March 18, 2023, NIMBUS THERAPEUTICS, MA / TAKEDA, JP
10 mins read

A potential next best-in-class allosteric TYK2 inhibitor exhibits strong Ph. II results for plaque psoriasis. Takeda Pharmaceuticals has announced positive results for TAK-279 in Ph. IIb for the treatment of moderate-to-severe plaque psoriasis (PsO). Just disclosed last year, TAK-279 (formerly known as NDI-034858) was acquired by Takeda from Nimbus in a recent $4 billion dollar deal. The Nimbus TYK2 research program was started to compete with BMS's deucravacitinib in a research collaboration with Celgene, including a Joint Steering Committee and Celgene scientists contributing, but after BMS's acquisition of Celgene, Nimbus had to firewall Celgene and sue for rights back to the molecule. This oral, allosteric TYK2 inhibitor reduced the severity of PsO for ~68% of patients at a 15 or…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: